in 2016 demonstrated that co-occurring LKB1 and KRAS mutations in pancreatic cancer GEMMs elicit significant epigenetic changes stemming from aberrant activity in the serine metabolic axis (37). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.